With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023, the Complement-Based Drug Development Summit is returning for
Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential, as Pepper Bio's Samantha Dale explains
Be part of the only industry focused event exclusively addressing discovery, translational and reverse translational challenges for Cytokine-Based drug developers.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
